These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24764355)

  • 21. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic utility of, and influence of tobacco usage and genetic predisposition on, immunoglobulin A, rheumatoid factor and anti-citrullinated peptide auto-antibodies in South African rheumatoid arthritis patients.
    Meyer P; Ally M; Hodkinson B; Anderson R; Tikly M
    Afr Health Sci; 2018 Jun; 18(2):295-303. PubMed ID: 30602956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis.
    Dewint P; Hoffman IE; Rogge S; Joos R; Union A; Dehoorne J; Delanghe J; Veys EM; De Keyser F; Elewaut D
    Rheumatology (Oxford); 2006 Feb; 45(2):204-8. PubMed ID: 16188943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.
    Heidari B; Firouzjahi A; Heidari P; Hajian K
    Ann Saudi Med; 2009; 29(6):467-70. PubMed ID: 19847085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis.
    Vittecoq O; Incaurgarat B; Jouen-Beades F; Legoedec J; Letourneur O; Rolland D; Gervasi G; Ménard JF; Gayet A; Fardellone P; Daragon A; Jolivet M; le Loët X; Tron F
    Clin Exp Immunol; 2004 Jan; 135(1):173-80. PubMed ID: 14678280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis.
    Zeng X; Ai M; Tian X; Gan X; Shi Y; Song Q; Tang F
    J Rheumatol; 2003 Jul; 30(7):1451-5. PubMed ID: 12858440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis.
    Van Hoovels L; Jacobs J; Vander Cruyssen B; Van den Bremt S; Verschueren P; Bossuyt X
    Ann Rheum Dis; 2018 May; 77(5):667-677. PubMed ID: 29363510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis.
    Gonzalez SM; Payne JB; Yu F; Thiele GM; Erickson AR; Johnson PG; Schmid MJ; Cannon GW; Kerr GS; Reimold AM; Sokolove J; Robinson WH; Mikuls TR
    J Periodontol; 2015 Feb; 86(2):222-31. PubMed ID: 25299390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis.
    Lutteri L; Malaise M; Chapelle JP
    Clin Chim Acta; 2007; 386(1-2):76-81. PubMed ID: 17826752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.
    Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Orbach H; Gerli R; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):197-202. PubMed ID: 16295525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
    Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
    Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
    Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
    Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts.
    Humphreys JH; van Nies JA; Chipping J; Marshall T; van der Helm-van Mil AH; Symmons DP; Verstappen SM
    Arthritis Res Ther; 2014 Dec; 16(6):483. PubMed ID: 25471696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors Associated with Erosive Arthritis in Rheumatoid Arthritis and Other Connective Tissue Diseases: A Retrospective Study From a Southern Chinese Population.
    Yuan S; Chen D; Xiao Y; Lao M; Qiu Q; Liang L; Yang X
    J Clin Rheumatol; 2016 Jan; 22(1):22-9. PubMed ID: 26693623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study.
    Nell-Duxneuner V; Machold K; Stamm T; Eberl G; Heinzl H; Hoefler E; Smolen JS; Steiner G
    Ann Rheum Dis; 2010 Jan; 69(1):169-74. PubMed ID: 19153104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
    Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
    Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.
    Ursum J; Bos WH; van de Stadt RJ; Dijkmans BA; van Schaardenburg D
    Arthritis Res Ther; 2009; 11(3):R75. PubMed ID: 19460147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.